Are Tirzepatide and Mounjaro the Same Medicine?

Step 1: understand the naming convention before you search

Pharmaceutical companies register a brand name alongside the scientific (generic) name of every new medicine. When a drug is newly approved, the brand name tends to dominate early searches and prescriptions; as it matures, the generic name appears more in clinical literature. Tirzepatide followed that pattern exactly. Eli Lilly submitted it to the MHRA under the brand name Mounjaro, which now appears on the box, the pen and your prescription. Tirzepatide is what pharmacists and clinicians write in guidelines, trial papers and drug databases like the BNF tirzepatide entry.

If you have seen a headline about "tirzepatide results" and wondered whether a different product was being discussed, it was not, and our page on whether Mounjaro and tirzepatide are the same thing walks through exactly why that is the case. Every study (including the large SURMOUNT-1 trial) tested the same molecule that is now sold as Mounjaro. No licensed UK alternative exists under a different name.

One quick check worth doing: if you find a website selling what it calls "tirzepatide" without the Mounjaro branding, look it up on the GPhC pharmacy register before engaging further. Legitimate dispensing always involves a labelled, licensed product from a verified supply chain, not loose ingredient names.

Step 2: understand what tirzepatide actually does in the body

Tirzepatide works by attaching to two receptors simultaneously: the GIP receptor and the GLP-1 receptor. Both are involved in the body's response to eating, they signal fullness, slow the rate at which the stomach empties and influence how the body handles blood sugar. Most other weight-management injections target only the GLP-1 pathway; tirzepatide's dual action is what makes it clinically distinct as a treatment option.

Because gastric emptying is slower, many people feel full with smaller portions, and that feeling often arrives before finishing a meal rather than long after. Appetite signals also change over weeks of treatment, though experience varies between individuals. Our Mounjaro overview covers the mechanism in more detail if you want the fuller picture.

Side effects follow directly from this mechanism. Nausea, loose stools, constipation and indigestion are the most common, particularly in the first few weeks or after a dose step. They are not universal and frequently ease as the body adjusts. The treatment starts at 2.5 mg (a dose whose job is to let your system settle rather than produce rapid change) before the prescriber considers moving upward.

Step 3: know which licence applies to you

In the UK, tirzepatide (Mounjaro) holds two licences: one for weight management in adults and one for type 2 diabetes. The weight-management licence covers adults with a BMI of 30 or above, or a BMI of 27 or above where a weight-related health condition is also present, such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance.

NICE assessed tirzepatide specifically for weight management in its appraisal TA1026, published in December 2024, and recommended it for NHS use under a phased rollout tied to BMI and the number of weight-related conditions present. Private routes, like the assessment we offer at our consultation service, follow the licensed criteria rather than the NHS phase timetable. Neither route supplies the medicine to someone who has not had a clinical assessment first, that is a legal requirement, not a commercial choice.

It is also worth noting that tirzepatide is a Black Triangle (▼) medicine, meaning it carries additional MHRA monitoring while longer-term real-world safety data are gathered. That monitoring flag does not mean the product is new to clinical use; it reflects the MHRA's standard practice for recently approved medicines. Questions about how the wider weight-loss treatment landscape compares are answered on our treatment overview.

Step 4: know what this medicine is not

A few names are worth distinguishing clearly. Zepbound is the brand name Eli Lilly uses in the United States for tirzepatide, it does not exist as a UK product and cannot be ordered through any UK pharmacy. If a seller is offering Zepbound in the UK, treat that as a warning sign rather than a bargain. Separately, Ozempic contains a different active ingredient (semaglutide) and is licensed in the UK for type 2 diabetes, not weight management. Confusing these names is common online, but if you want a clear answer to whether tirzepatide is the same as Mounjaro, the prescriptions, licences and products are covered in detail there.

Readers who want to explore how tirzepatide relates to GLP-1 medicines more broadly will find that comparison useful context. Those curious about how Mounjaro is priced in the UK private market can read about the cost picture and what legitimate pricing actually includes. Our clinical team page explains the prescribing oversight behind every consultation. If any of this raises further questions, a prescriber at our pharmacy is available to discuss your specific situation.